Fazirsiran
RNA / oligonucleotide
Evidence outlook · registrational
Alpha-1 Antitrypsin Deficiency: registrational readout pending
Its supporting mid-stage studies have completed. Registrational readout expected around 2028-08-26.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05677971 NCT05677971 · Alpha-1 Antitrypsin Deficiency Registry: NCT05677971 | 3 | Reduction From Baseline of at Least 1 Stage of Histologic Fibrosis (METAVIR Staging) in the Centrally Read Liver Biopsy at Week 106 in AATD-LD With METAVIR Stage F2 and F3 Fibrosis (Baseline, Week 106) 2029-01-17 | In progress: results expected 17 Jan 2029 | not yet graded | link ↗ |
View 1 more trial
NCT06165341 NCT06165341 · Alpha-1 Antitrypsin Deficiency Registry: NCT06165341 | 3 | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) (From start of study drug administration up to End of study (EOS) (Week 124)); Number of Participants With Clinically Significant Change From Baseline in Pulmonary Function Parameters (From start of study drug administration up to EOS (Week 124)); Change From Baseline in Whole Lung 15th Percentile Density as Measured by Computed Tomography (CT) Lung Densitometry (Baseline up to Week 100); Number of Participants With Clinically Significant Changes in Vital Signs (From start of study drug administration up to EOS (Week 124)); Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Parameters (From start of study drug administration up to EOS (Week 124)); Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters (From start of study drug administration up to EOS (Week 124)) 2028-08-26 | In progress: results expected 26 Aug 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other SERPINA1 drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Alpha-1 Antitrypsin Deficiency: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Fazirsiran: this drug | Phase 3 | RNA / oligonucleotide | SERPINA1 | not yet graded | No reviewed efficacy summary in this indication | |
| Alvelestat | Phase 2 | Small molecule | Neutrophil elastase | Partial signal | NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively). | |
| BEAM-302 | Phase 1/2 | Gene therapy / editing | SERPINA1 PiZ mutation (E342K) | not yet graded | No reviewed efficacy summary in this indication | |
| TSRA-196 | Phase 1/2 | Gene therapy / editing | SERPINA1 | not yet graded | No reviewed efficacy summary in this indication | |
| WVE-006 | Phase 1/2 | RNA / oligonucleotide | SERPINA1 Z-allele mRNA (ADAR-mediated editing) | not yet graded | No reviewed efficacy summary in this indication | |
| KB408 | Phase 1 | Gene therapy / editing | SERPINA1 (alpha-1 antitrypsin; gene replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| Efdoralprin Alfa | —(overall) | Protein / enzyme therapeutic | Alpha-1 antitrypsin (AAT) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Fazirsiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.